Rarity Bioscience provides ultrasensitive multiplex assays for detecting rare nucleic acid sequences in biological samples like liquid biopsies for research, pharma and clinic. Our technology platform – Rarity SafeLock – permits read-out based on flow cytometry and already existing instrumentation. The company was founded 2021 based on a discovery by Dr Lei Chen, PhD in molecular biology and a member of Professor Ulf Landegrens team at the Department of Immunology, Genomics and Pathology at Uppsala University.
Location: Sweden, Uppsala
Employees: 1-10
Total raised: $10.23M
Founded date: 2021
Investors 1
| Date | Name | Website |
| 07.02.2023 | Novalis Bi... | noval.is |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 08.08.2024 | - | $7.1M | - |
| 05.02.2023 | Seed | $536.5K | - |
| 29.11.2022 | Seed | $2.6M | - |
Mentions in press and media 3
| Date | Title | Description |
| 08.08.2024 | Rarity Bioscience announces the successful closure of a €6.5 million funding round | June, 18th 2024, Uppsala, Sweden. Rarity Bioscience, a pioneering molecular biotech company, is pleased to announce the successful closure of a €6.5 million funding round.... |
| 29.11.2022 | Rarity Bioscience Raises €2,5M in Seed Funding to Improve Cancer Care | With the aim to improve cancer diagnostics, Rarity Bioscience has raised €2,5 million to expands operations and product development within precision diagnostics and liquid biopsy. The seed round was led by founders and joined by new investo... |
| - | Rarity Bioscience | “1 mutation in 100 000 wild-types because sensitivity matters Radically improving cancer diagnostics Rarity superRCA is an ultrasensitive multiplex assay for detecting rare nucleic acid sequences in biological samples like liquid biopsies. ... |